135321-95-8Relevant academic research and scientific papers
Structure-based screening for the discovery of 1,2,4-oxadiazoles as promising hits for the development of new anti-inflammatory agents interfering with eicosanoid biosynthesis pathways
Bifulco, Giuseppe,Chini, Maria Giovanna,D'Auria, Maria Valeria,De Marino, Simona,Festa, Carmen,Giordano, Assunta,Hofstetter, Robert Klaus,Maione, Francesco,Potenza, Marianna,Saviano, Anella,Sciarretta, Martina,Werz, Oliver
, (2021/07/28)
The multiple inhibition of biological targets involved in pro-inflammatory eicosanoid biosynthesis represents an innovative strategy for treating inflammatory disorders in light of higher efficacy and safety. Herein, following a multidisciplinary protocol
ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE
-
Page/Page column 67; 81-82; 86, (2019/12/28)
Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
-
Page/Page column 61-62, (2019/12/28)
Disclosed herein are acylated active agents (e.g., acylated catechin polyphenols, acylated carotenoids, acylated mesalamines, acylated sugars, acylated shikimic acids, acylated ellagic acid, acylated ellagic acid analogue, and acylated hydroxybenzoic acids), active agent combinations (e.g., with a second agent that is a fatty acid) and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME
-
Page/Page column 82; 127; 128, (2019/01/06)
Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and/or acyls. Also disclosed are compositions containing multibiotic agents and methods of using the multibiotic agents.
Synthesis and antitumor activity of ATB-429 derivatives containing a nitric oxide-releasing moiety
Wang, Chunlan,Xia, Guimin,Liu, Xiujun,Zhang, Rui,Chai, Yun,Zhang, Jun,Li, Xiaoning,Yang, Yang,Wang, Juxian,Liu, Mingliang
, p. 2355 - 2359 (2016/04/20)
A series of novel ATB-429 (an anti-inflammatory candidate) derivatives containing a nitric oxide (NO)-releasing moiety were designed, synthesized and evaluated for their in vitro activity against six human cancer cell lines. Our results reveal that phenyl
NO- AND H2S- RELEASING COMPOUNDS
-
Paragraph 0082; 0083, (2016/10/11)
This disclosure relates to novel compounds containing an H2S releasing moiety and a nitric oxide (NO) releasing moiety covalently linked with a core (e.g., a salicylic acid moiety) and the use of such compounds in treating inflammatory diseases, including
Fragment screening reveals salicylic hydroxamic acid as an inhibitor of Trypanosoma brucei GPI GlcNAc-PI de-N-acetylase
Urbaniak, Michael D.,Capes, Amy S.,Crossman, Arthur,O'Neill, Sandra,Thompson, Stephen,Gilbert, Ian H.,Ferguson, Michael A.J.
, p. 54 - 58 (2014/03/21)
The zinc-metalloenzyme GlcNAc-PI de-N-acetylase is essential for the biosynthesis of mature GPI anchors and has been genetically validated in the bloodstream form of Trypanosoma brucei, which causes African sleeping sickness. We screened a focused library
COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
-
Paragraph 00109; 00112-00113, (2014/05/24)
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of
NOVEL DERIVATIVES OF MESALAZINE, PROCESS OF THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES
-
Paragraph 0082; 0083, (2013/04/10)
The present invention refers to the compounds corresponding to the following general formula (I): wherein: R═C4-C8 alkanoyl; andX═NH—R1 where R1═H, or an amine protecting group;and/or the pharmaceutically accept
Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome P450-activated prodrugs
Huttunen, Kristiina M.,Tani, Niina,Juvonen, Risto O.,Raunio, Hannu,Rautio, Jarkko
, p. 532 - 537 (2013/08/24)
Four novel cyclic phosphates of the anti-inflammatory agent 5-aminosalicylic acid (5-ASA) were designed and synthesized as cytochrome P450 (CYP)-activated prodrugs. These prodrugs can be used for targeting into gut wall, since these types of cyclic phosph
